Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL study of zibotentan and dapagliflozin in liver cirrhosis with portal hypertension
NL-OMON59239Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of zibotentan and dapagliflozin in Cirrhosis and Portal Hypertension (PH) (5 arms), sponsored by AstraZeneca. Primary endpoint: Absolute change in hepatic venous pressure gradient. Started Apr 2023; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on NL-OMON59239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59239.